Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection
暂无分享,去创建一个
D. Hess | A. Ergul | Lin Xu | S. Fagan | D. Pollock | Maribeth H. Johnson | A. Kozak | W. Hill | A. Kozák
[1] R. Chen,et al. Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation , 2004, Circulation.
[2] John H. Zhang,et al. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. , 2004, American journal of physiology. Heart and circulatory physiology.
[3] J. Leonardi-Bee,et al. High blood pressure in acute stroke and subsequent outcome: a systematic review. , 2004, Hypertension.
[4] M. Forsting,et al. The Angiotensin II Type 1—Receptor Blocker Candesartan Increases Cerebral Blood Flow, Reduces Infarct Size, and Improves Neurologic Outcome after Transient Cerebral Ischemia in Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] R. Knight,et al. Single slice method for quantification of hemorrhagic transformation using direct ELISA , 2004, Neurological research.
[6] T. Unger,et al. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats , 2003, Journal of hypertension.
[7] S. Mayer,et al. Blood pressure reduction in ischemic stroke , 2003, Neurology.
[8] H. Diener,et al. The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.
[9] G. Mancia,et al. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. , 2003, Journal of hypertension.
[10] R. Grubb,et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association , 2003, Stroke.
[11] P. Sandercock,et al. Blood Pressure and Clinical Outcomes in the International Stroke Trial , 2002, Stroke.
[12] Y. Katayama,et al. Hemorrhagic Transformation After Fibrinolysis With Tissue Plasminogen Activator: Evaluation of Role of Hypertension With Rat Thromboembolic Stroke Model , 2001, Stroke.
[13] L. Murri,et al. Transient autonomic nervous system dysfunction during hyperacute stroke , 2000, Acta neurologica Scandinavica.
[14] JurajCulman,et al. Blockade of Central Angiotensin AT1 Receptors Improves Neurological Outcome and Reduces Expression of AP-1 Transcription Factors After Focal Brain Ischemia in Rats , 1999 .
[15] T. Herdegen,et al. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. , 1999, Stroke.
[16] Á. Chamorro,et al. Blood pressure and functional recovery in acute ischemic stroke. , 1998, Stroke.
[17] P. Lyden,et al. Acute Hypertension Promotes Hemorrhagic Transformation in a Rabbit Embolic Stroke Model: Effect of Labetalol , 1998, Experimental Neurology.
[18] S. Fagan,et al. Acute Hypertension, but Not Thrombolysis, Increases the Incidence and Severity of Hemorrhagic Transformation Following Experimental Stroke in Rabbits , 1996, Experimental Neurology.
[19] V. Hachinski,et al. Autonomic and myocardial changes in middle cerebral artery occlusion: stroke models in the rat , 1989, Brain Research.
[20] K. Lamers,et al. Blood pressure and both venous and urinary catecholamines after cerebral infarction , 1988, Clinical Neurology and Neurosurgery.
[21] L. Pitts,et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. , 1986, Stroke.
[22] J. Zivin,et al. Hypertension in acute ischemic strokes. Not to treat. , 1985, Archives of neurology.
[23] J. Spence,et al. Hypertension in acute ischemic strokes. Treat. , 1985, Archives of neurology.
[24] M. Giroud,et al. Risk factors for primary cerebral hemorrhage: a population-based study--the Stroke Registry of Dijon. , 1995, Neuroepidemiology.
[25] P. Weinstein,et al. Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.